PwPepwise

Survodutide

Weight Loss

a.k.a. BI 456906

GLP-1 / glucagon dual agonist

Survodutide (also known as BI 456906) is an injectable peptide that simultaneously activates two hormone receptors in the body — the glucagon receptor.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Obesity (without type 2 diabetes)0.6 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.76 wks
Obesity with type 2 diabetes3.6 mgWeeklySubcutaneousInjected just under the skin, into the fat layer.76 wks
fatty liver and liver fibrosis2.4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.7 yrs

Approximate values pulled from the research — double-check before dosing.

§01Summary

Survodutide (also known as BI 456906) is an injectable peptide that simultaneously activates two hormone receptors in the body — the glucagon receptor and the GLP-1 receptor — working together to reduce appetite, increase energy burning, and improve liver health. This dual-action approach distinguishes it from existing GLP-1-only medications like semaglutide and may offer enhanced metabolic benefits.

In clinical trials, survodutide produces meaningful, dose-dependent weight loss of up to approximately 15% of body weight at the highest tested dose over 46 weeks in people with obesity2, and reduces blood sugar levels in people with type 2 diabetes3. For liver disease, survodutide significantly improves the histological features of metabolic-associated steatohepatitis (MASH) — a serious form of fatty liver disease — with response rates of 47–62% across doses compared to 14% for placebo1. A network meta-analysis ranked survodutide second among all agents studied for MASH resolution, behind only pegozafermin7. Gastrointestinal side effects such as nausea, diarrhea, and vomiting are the most commonly reported adverse events1,2. Survodutide is currently in large Phase 3 trials evaluating weight loss in obesity with and without type 2 diabetes, as well as long-term liver outcomes in MASH4,5,6.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Survodutide (BI 456906) is a synthetic acylated peptide designed as a balanced dual agonist at the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) — two structurally related class B G-protein-coupled receptors that play complementary roles in glucose homeostasis and energy metabolism. Unlike pure GLP-1 receptor agonists, survodutide achieves co-activation of both receptors, integrating the appetite-suppressive and insulinotropic actions of GLP-1R signaling with the energy-expenditure-enhancing, hepatic fat-mobilizing, and lipolytic effects mediated by GCGR signaling.

GLP-1R activation by survodutide stimulates glucose-dependent insulin secretion, suppresses postprandial glucagon release, slows gastric emptying, and reduces appetite via central hypothalamic pathways. GCGR activation stimulates hepatic glycogenolysis and gluconeogenesis, promotes adipose tissue lipolysis, increases energy expenditure through thermogenic mechanisms, and drives hepatic fatty acid oxidation — the latter being particularly relevant to the compound's activity in MASH. The dissociation between the HbA1c and body weight dose-response curves observed in clinical trials supports this mechanistic framework: glycemic control appears to plateau at lower doses (reflecting GLP-1R saturation), while weight loss continues to increase with higher doses (reflecting additional GCGR-driven energy expenditure)3.

Pharmacodynamic target engagement has been confirmed in humans through biomarker surrogates: reduced plasma alanine levels reflect GCGR activation (hepatic amino acid catabolism), and suppressed circulating glucagon levels confirm GLP-1R-mediated inhibition of alpha-cell glucagon secretion11. A meta-analysis further confirmed that survodutide significantly reduces fasting glucagon levels by approximately 7 pmol/L versus placebo, consistent with sustained GLP-1R agonism9.

Survodutide is administered subcutaneously once weekly; drug exposure increases proportionally with dose escalation, and peak-to-trough pharmacokinetic profiles favor once-weekly over twice-weekly dosing at equivalent total weekly doses — a finding that suggests peak plasma exposure may be a driver of efficacy rather than time-averaged exposure alone11. The acylation of the peptide backbone confers extended half-life through albumin binding, enabling the once-weekly dosing regimen. Gastrointestinal adverse effects, which are the predominant tolerability limitation, are thought to arise from GLP-1R-mediated slowing of gastric emptying and direct enteric effects, with transient delayed gastric emptying documented at higher doses during early dose-escalation11. Slower dose-escalation schedules may mitigate GI tolerability3. Central nervous system effects of survodutide on appetite regulation and reward circuitry are being actively characterized through fMRI-based mechanistic studies16.

§04Evidence & efficacy

Evidence base
121Studies
56Human
0Animal

Obesity: Survodutide produces dose-dependent reductions in body weight in adults with obesity. In a Phase 2 RCT, mean weight loss at week 46 ranged from -6.2% at the lowest dose (0.6 mg) to -14.9% at the highest dose (4.8 mg), compared to -2.8% for placebo, with all active doses achieving statistically significant superiority2. Females and participants with lower baseline BMI appear to experience greater proportional weight loss12. A meta-analysis of available RCTs confirmed significant reductions in body weight (WMD -6.7 kg), waist circumference (WMD -7.09 cm), and BMI with survodutide versus placebo9.

Type 2 diabetes and glycemic control: Survodutide reduces HbA1c in a dose-dependent manner in people with type 2 diabetes, with higher doses (≥1.8 mg once weekly) achieving greater body weight reductions than semaglutide 1.0 mg at 16 weeks (-8.7% vs. -5.3%)3. The HbA1c-lowering effect appears to plateau at mid-range doses while weight reduction continues to increase with higher doses, suggesting that glucagon receptor agonism contributes primarily to weight loss rather than glycemic improvement3. A meta-analysis reported a pooled HbA1c reduction of -0.66% and fasting glucagon reduction of -7 pmol/L versus placebo9.

MASH and liver fibrosis: Survodutide significantly improves MASH histology. In the Phase 2 MASH trial, the primary endpoint of MASH improvement without fibrosis worsening was achieved in 47–62% of survodutide-treated participants versus 14% for placebo (p<0.001 for all doses), with the 4.8 mg dose showing the highest response rate1. Liver fat reduction of ≥30% was achieved in 57–67% of survodutide recipients versus 14% with placebo1. In a network meta-analysis of 29 RCTs, survodutide ranked second for MASH resolution without fibrosis worsening (SUCRA 90.87), behind only pegozafermin, and ahead of tirzepatide7. Survodutide may also improve liver fibrosis by at least one stage, with rates of 34–36% across dose groups versus 22% for placebo1, though this effect has not yet achieved statistical separation from placebo in available trials. Phase 3 trials evaluating hard liver-related clinical outcomes in both noncirrhotic MASH with fibrosis and compensated MASH cirrhosis are actively underway5,6.

§05Safety

Survodutide's most consistently observed adverse effects are gastrointestinal in nature. Across trials, nausea affected approximately 66% of survodutide-treated participants versus 23% for placebo, diarrhea occurred in approximately 49% versus 23%, and vomiting in approximately 41% versus 4% in the Phase 2 MASH trial1. In the obesity Phase 2 trial, gastrointestinal adverse events were reported in 75% of survodutide recipients versus 42% on placebo, and overall adverse events occurred in 91% versus 75% of participants respectively2. In the type 2 diabetes Phase 2 trial, adverse events occurred in 77.8% of survodutide-treated participants compared to 52.5% on placebo and 52.0% on open-label semaglutide3. These rates are meaningfully higher than comparator arms, though the nature of adverse events is consistent with the GLP-1/glucagon receptor agonist pharmacological class.

Discontinuation due to adverse events was higher with survodutide than placebo across trials, with MASH trial discontinuation rates of 16.4–23.0% for survodutide versus 2.7% for placebo8. In a Phase 1 study in Japanese men, 37% of survodutide-treated participants withdrew from dose escalation due to adverse events, with the highest withdrawal rate (66.7%) in the 4.8 mg once-weekly group11. A single participant in a Phase 1 study experienced an amylase increase, a potential pancreatic signal that warrants continued monitoring in larger trials11.

Serious adverse events were comparable between survodutide and placebo arms in the MASH Phase 2 trial (8% vs. 7%), suggesting that while tolerability burden is elevated, serious harm does not appear disproportionate at tested doses1. A dedicated cardiac safety study evaluating QT/QTc interval effects at multiple doses and steady-state exposure is underway10, and a large Phase 3 cardiovascular outcomes trial is actively enrolling to characterize MACE risk in high-risk cardiovascular and chronic kidney disease populations4.

§06History

Survodutide (internal development code BI 456906) was developed by Boehringer Ingelheim as part of a broader effort to advance next-generation incretin-based therapies beyond pure GLP-1 receptor agonism. The compound was designed to co-activate both the glucagon receptor and GLP-1 receptor in a balanced fashion, capitalizing on growing preclinical evidence that glucagon receptor agonism could amplify weight loss and hepatic fat reduction beyond what GLP-1R agonism alone achieves.

Early Phase 1 clinical evaluation established the pharmacokinetic and pharmacodynamic properties of survodutide in human subjects, including a dedicated study in Japanese men that confirmed dose-proportional drug exposure, dual receptor target engagement via biomarker surrogates, and an initial characterization of the GI tolerability profile11. This laid the foundation for a Phase 2 dose-finding trial in obesity, published in The Lancet Diabetes & Endocrinology in 2024, which demonstrated dose-dependent weight loss of up to approximately 14.9% at the 4.8 mg dose over 46 weeks2. A parallel Phase 2 program in type 2 diabetes generated head-to-head comparisons with semaglutide and a key mechanistic insight regarding divergent dose-response curves for glycemic versus weight outcomes3.

The MASH indication emerged as a high-priority development target, with a Phase 2 histology-based RCT published in 2024 demonstrating significant superiority over placebo for MASH resolution1, and a network meta-analysis subsequently positioning survodutide among the most efficacious agents in the MASH pipeline7. By 2023–2024, Boehringer Ingelheim had initiated a comprehensive Phase 3 program spanning obesity without diabetes13, obesity with type 2 diabetes14, noncirrhotic MASH with fibrosis6, compensated MASH cirrhosis5, and a cardiovascular outcomes trial4, reflecting broad regulatory ambition across multiple high-prevalence metabolic indications.

§07References